Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis

Journal of Biomedical Nanotechnology

Volumn 7, Issue 1, 2011, Pages 123-124

  Singodia, D ^a   Khare, P ^a   Dube, A ^a   Talegaonkar, S ^b   Khar, R K ^b   Mishra, P R ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Alginate; Immunoenhancement; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; CHEMOTHERAPEUTIC ACTIVITY; CURE RATE; IMMUNOENHANCEMENT; PARASITE-; PERFORMANCE EVALUATION; VISCERAL LEISHMANIASIS;

ZETA POTENTIAL;

ALGINATE;

ALGINIC ACID; AMPHOTERICIN B LIPID COMPLEX; NANOCOATING; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; GLUCURONIC ACID; HEXURONIC ACID; LIPID; NANOCAPSULE;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG COATING; DRUG FORMULATION; DRUG POTENTIATION; IMMUNOSTIMULATION; MACROPHAGE; MACROPHAGE ACTIVATION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; VISCERAL LEISHMANIASIS; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; EVALUATION; LEISHMANIA; PHYSIOLOGY; TREATMENT OUTCOME;

ALGINATES; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CELL SURVIVAL; GLUCURONIC ACID; HEXURONIC ACIDS; LEISHMANIA; LIPIDS; NANOCAPSULES; TREATMENT OUTCOME;

EID: 79957727187     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1232     Document Type: Article

References (4)

1. F. Chappuis, S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J. Alvar, and M. Boelaert, Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5, 873 (2007).
2. J. Berman, ABLE: A new and improved amphotericin B for visceral leishmaniasis? Am. J. Trop. Med. Hyg. 80, 689 (2009).
3. A. O. Tzianabos, Polysaccharide immuno-modulators as therapeutic agents: Structural aspects and biologic function. Clin. Microbiol. Rev. 13, 523 (2000).
4. G. Lopez-Berestein, M. Rosenblum, and R. Mehta, Altered tissue distribution of amphotericin-B by liposomal encap-sulation: Comparison of normal mice to mice infected with Candida albicans. Cancer Drug Delivery 1, 199 (1984).